Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird Sells 85,561 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 85,561 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $31.01, for a total value of $2,653,246.61. Following the completion of the sale, the chief operating officer now directly owns 630,986 shares in the company, valued at $19,566,875.86. This trade represents a 11.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Melissa Baird also recently made the following trade(s):

• On Monday, November 18th, Melissa Baird sold 58,750 shares of Hims & Hers Health stock. The stock was sold at an average price of $21.04, for a total value of $1,236,100.00.
• On Monday, October 7th, Melissa Baird sold 58,750 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.57, for a total value of $1,149,737.50.

Hims & Hers Health Trading Down 0.3 %

NYSE:HIMS opened at $30.10 on Friday. Hims & Hers Health, Inc. has a 1 year low of $8.09 and a 1 year high of $35.02. The stock has a market cap of $6.58 billion, a price-to-earnings ratio of 68.41 and a beta of 1.25. The stock has a 50-day moving average price of $24.54 and a two-hundred day moving average price of $20.86.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the prior year, the company posted ($0.04) earnings per share. Hims & Hers Health’s revenue was up 77.1% on a year-over-year basis. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on HIMS shares. Needham & Company LLC started coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Deutsche Bank Aktiengesellschaft raised their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price objective for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. Finally, TD Cowen reiterated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and an average target price of $21.43.

Institutional Trading of Hims & Hers Health

Several institutional investors and hedge funds have recently bought and sold shares of HIMS. Cetera Advisors LLC acquired a new position in Hims & Hers Health during the first quarter worth approximately $396,000. SG Americas Securities LLC acquired a new position in shares of Hims & Hers Health in the second quarter valued at approximately $2,223,000. Nisa Investment Advisors LLC grew its position in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the last quarter. Legacy Capital Group California Inc. acquired a new position in shares of Hims & Hers Health in the second quarter valued at approximately $1,699,000. Finally, Bank of New York Mellon Corp grew its position in shares of Hims & Hers Health by 67.5% in the second quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock valued at $13,701,000 after purchasing an additional 273,473 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.